SAN FRANCISCO, Feb. 28, 2012 /PRNewswire/ — Vista Partners announced today that it has updated coverage on PositiveID Corporation (OTCBB: PSID) (“The Company” or “PSID”); and revised its twelve month target price to $0.38. Ross Silver, Principal Analyst at Vista Partners stated, “The Company’s MicroFluidic Systems subsidiary is attempting to secure a portion of the $3.1B Homeland Defense BioWatch pathogen detection contract. The Company is jointly demonstrating its M-BAND device with The Boeing Company and Hamilton Sundstrand at a bioterrorism conference this week.” Mr. Silver continues, “We believe the Company’s diabetes management products; both FDA approved and under clinical development, could become standards of care. The Company has entered into a partnership with IDEAL LIFE, Inc., a health management leader, to bring iglucose to market. IDEAL LIFE will market iglucose to its large network of customers, including insurance companies, hospitals, and other health care providers. By partnering with IDEAL LIFE, the Company hopes to accelerate market adoption of iglucose. The company anticipates iglucose to be commercially available in the first half of 2012.”
To download a FREE copy of the PositiveID Corporation research report, please visit http://www.vistapglobal.com and click the “download research” icon to gain access to the report.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm’s professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.
877.215.4813 or email@example.com
SOURCE Vista Partners